DMRA Stock: Price, Earnings History and SEC Filings
Damora Therapeutics, Inc. (DMRA) last traded at $21.49, down 2.36% on the latest session and up 1.0% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.39 against an analyst estimate of $-0.38, a miss of 2.6%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
DMRA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 10, 2026 | $-0.39 | $-0.38 | -2.63% |
| Mar 2026 | May 12, 2026 | $-0.62 | $-0.21 | -195.24% |
DMRA beat the analyst EPS estimate in 0 of its last 2 reported quarters. Source: Nasdaq.
DMRA financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | – | -$210M | – | – | $3.98 |
| 2024 | – | -$21M | – | – | $-18.53 |
| 2023 | – | -$38M | – | – | $-36.08 |
| 2022 | – | -$62M | -$43M | – | $-2.43 |
| 2021 | – | -$52M | -$53M | – | $-2.05 |
| 2020 | – | -$35M | – | – | – |
| 2019 | – | -$37M | – | – | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for DMRA
- 10-Q · Aug 10, 2026
- 8-K · Jul 20, 2026Material agreement, Bylaw change, Regulation FD disclosure
- 8-K · Jun 17, 2026Shareholder vote
- 10-Q · May 12, 2026
- 8-K · May 4, 2026Officer or director change, Financial statements and exhibits
- DEF 14A · Apr 29, 2026
- 8-K · Apr 20, 2026Financial statements and exhibits
- 8-K · Mar 23, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 10-K · Mar 19, 2026
- 8-K · Mar 10, 2026Results of operations, Bylaw change, Regulation FD disclosure
Insider filing activity
DMRA insiders filed 2 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
DMRA news
- DMRA - Damora Therapeutics, Inc.Oct 26, 2026 · seekingalpha.com
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc. (DMRA) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.